Causes, consequences, and treatment of osteoporosis in men

References

• Hannan MT Felson DT Dawson-Hughes B Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study J Bone Miner Res 2000 15 4 710 720 10780863
   PubMed Web of Science ®Google Scholar
• Khosla S Update in male osteoporosis J Clin Endocrinol Metab 2010 95 1 3 10 20056806
   PubMed Web of Science ®Google Scholar
• Melton LJ3rd Chrischilles EA Cooper C Lane AW Riggs BL Perspective. How many women have osteoporosis? J Bone Miner Res 1992 7 9 1005 1010 1414493
   PubMed Web of Science ®Google Scholar
• Binkley N A perspective on male osteoporosis Best Pract Res Clin Rheumatol 2009 23 6 755 768 19945687
   PubMed Web of Science ®Google Scholar
• Edelstein OE What do Israeli osteoporotic men know and do about their disease? J Osteoporos 2011 2011 719862 21772976
   PubMedGoogle Scholar
• McLeod KM Johnson CS A systematic review of osteoporosis health beliefs in adult men and women J Osteoporos 2011 2011 197454 21941678
   PubMedGoogle Scholar
• Solimeo SL Living with a ‘women’s disease’: risk appraisal and management among men with osteoporosis J Mens health 2011 8 3 185 191 22125585
   PubMed Web of Science ®Google Scholar
• Madeo B Zirilli L Caffagni G The osteoporotic male: overlooked and undermanaged? Clin Interv Aging 2007 2 3 305 312 18044181
   PubMed Web of Science ®Google Scholar
• Rao SS Budhwar N Ashfaque A Osteoporosis in men Am Fam Physician 2010 82 5 503 508 20822086
   PubMed Web of Science ®Google Scholar
• Seeman E Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis Osteoporos Int 2003 14 Suppl 3 S2 S8 12730770
   PubMed Web of Science ®Google Scholar
• Lambert JK Zaidi M Mechanick JI Male osteoporosis: epidemiology and the pathogenesis of aging bones Curr Osteoporos Rep 2011 9 4 229 236 21853294
   PubMedGoogle Scholar
• Compston J Cooper A Cooper C Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Maturitas 2009 62 2 105 108 19135323
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation Making a diagnosis Available from: http://www.nof.org/articles/8 Accessed October 16, 2012
   Google Scholar
• Gates BJ Das S Management of osteoporosis in elderly men Maturitas 2011 69 2 113 119 21481552
   PubMed Web of Science ®Google Scholar
• Ryan CS Petkov VI Adler RA Osteoporosis in men: the value of laboratory testing Osteoporos Int 2010 22 6 1845 1853 20936403
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B Racial/ethnic considerations in making recommendations for vitamin D for adult and elderly men and women Am J Clin Nutr 2004 80 Suppl 6 1763S 1766S 15585802
   PubMed Web of Science ®Google Scholar
• Leder BZ LeBlanc KM Schoenfeld DA Eastell R Finkelstein JS Differential effects of androgens and estrogens on bone turnover in normal men J Clin Endocrinol Metab 2003 88 1 204 210 12519853
   PubMed Web of Science ®Google Scholar
• Mohr BA Guay AT O’Donnell AB McKinlay JB Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study Clin Endocrinol (Oxf) 2005 62 1 64 73 15638872
   PubMed Web of Science ®Google Scholar
• Feldman HA Longcope C Derby CA Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study J Clin Endocrinol Metab 2002 87 2 589 598 11836290
   PubMed Web of Science ®Google Scholar
• Morley JE Kaiser FE Perry HM3rd Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men Metabolism 1997 46 4 410 413 9109845
   PubMed Web of Science ®Google Scholar
• Muller M den Tonkelaar I Thijssen JH Grobbee DE van der Schouw YT Endogenous sex hormones in men aged 40–80 years Eur J Endocrinol 2003 149 6 583 589 14641001
   PubMed Web of Science ®Google Scholar
• Svartberg J Midtby M Bonaa KH Sundsfjord J Joakimsen RM Jorde R The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study Eur J Endocrinol 2003 149 2 145 152 12887292
   PubMed Web of Science ®Google Scholar
• Vermeulen A Kaufman JM Giagulli VA Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males J Clin Endocrinol Metab 1996 81 5 1821 1826 8626841
   PubMed Web of Science ®Google Scholar
• Ferrini RL Barrett-Connor E Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men Am J Epidemiol 1998 147 8 750 754 9554416
   PubMed Web of Science ®Google Scholar
• Litman HJ Bhasin S Link CL Araujo AB McKinlay JB Serum androgen levels in black, Hispanic, and white men J Clin Endocrinol Metab 2006 91 11 4326 4334 16912139
   PubMed Web of Science ®Google Scholar
• Yeap BB Testosterone and ill-health in aging men Nat Clin Pract Endocrinol Metab 2009 5 2 113 121 19165223
   PubMedGoogle Scholar
• Khosla S Amin S Orwoll E Osteoporosis in men Endocr Rev 2008 29 4 441 464 18451258
   PubMed Web of Science ®Google Scholar
• Sinnesael M Boonen S Claessens F Gielen E Vanderschueren D Testosterone and the male skeleton: a dual mode of action J Osteoporos 2011 2011 240328 21941679
   PubMedGoogle Scholar
• LeBlanc ES Nielson CM Marshall LM The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men J Clin Endocrinol Metab 2009 94 9 3337 3346 19584177
   PubMed Web of Science ®Google Scholar
• Kurland ES Cosman F McMahon DJ Rosen CJ Lindsay R Bilezikian JP Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers J Clin Endocrinol Metab 2000 85 9 3069 3076 10999788
   PubMed Web of Science ®Google Scholar
• Van Pottelbergh I Goemaere S Zmierczak H Kaufman JM Perturbed sex steroid status in men with idiopathic osteoporosis and their sons J Clin Endocrinol Metab 2004 89 10 4949 4953 15472190
   PubMed Web of Science ®Google Scholar
• Trouvin AP Goeb V Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss Clin Interv Aging 2011 5 345 354 21228900
   PubMed Web of Science ®Google Scholar
• Israeli RS Ryan CW Jung LL Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy J Urol 2008 179 2 414 423 18076933
   PubMed Web of Science ®Google Scholar
• Liu H Paige NM Goldzweig CL Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline Ann Intern Med 2008 148 9 685 701 18458282
   PubMed Web of Science ®Google Scholar
• Lopez AM Pena MA Hernandez R Val F Martin B Riancho JA Fracture risk in patients with prostate cancer on androgen deprivation therapy Osteoporos Int 2005 16 6 707 711 15714259
   PubMed Web of Science ®Google Scholar
• Shahinian VB Kuo YF Freeman JL Goodwin JS Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 2005 352 2 154 164 15647578
   PubMed Web of Science ®Google Scholar
• Diamond TH Higano CS Smith MR Guise TA Singer FR Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies Cancer 2004 100 5 892 899 14983482
   PubMed Web of Science ®Google Scholar
• Daniell HW Dunn SR Ferguson DW Lomas G Niazi Z Stratte PT Progressive osteoporosis during androgen deprivation therapy for prostate cancer J Urol 2000 163 1 181 186 10604342
   PubMed Web of Science ®Google Scholar
• Kiratli BJ Srinivas S Perkash I Terris MK Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer Urology 2001 57 1 127 132 11164157
   PubMed Web of Science ®Google Scholar
• Sardone LD Renlund R Willett TL Fantus IG Grynpas MD Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis Diabetes 2011 60 12 3271 3278 21998400
   PubMed Web of Science ®Google Scholar
• Debiais F Thiazolidinediones: antidiabetic agents with effects on bone Joint Bone Spine 2009 76 3 221 223 19362505
   PubMed Web of Science ®Google Scholar
• Grey A Thiazolidinedione-induced skeletal fragility – mechanisms and implications Diabetes Obes Metab 2009 11 4 275 284 18671797
   PubMed Web of Science ®Google Scholar
• Rosen CJ The rosiglitazone story – lessons from an FDA Advisory Committee meeting N Engl J Med 2007 357 9 844 846 17687124
   PubMed Web of Science ®Google Scholar
• Aubert RE Herrera V Chen W Haffner SM Pendergrass M Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes Diabetes Obes Metab 2010 12 8 716 721 20590749
   PubMed Web of Science ®Google Scholar
• Chakreeyarat S Saetung S Chailurkit LO Elevated vitamin D status in postmenopausal women on thiazolidinediones for type 2 diabetes Endocrine 2010 39 3 278 282 21069575
   PubMed Web of Science ®Google Scholar
• Carruthers M Trinick TR Jankowska E Traish AM Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol 2008 7 30 18922158
   PubMed Web of Science ®Google Scholar
• Lecka-Czernik B Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis Curr Osteoporos Rep 2010 8 4 178 184 20809203
   PubMedGoogle Scholar
• Soroceanu MA Miao D Bai XY Su H Goltzman D Karaplis AC Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis J Endocrinol 2004 183 1 203 216 15525588
   PubMed Web of Science ®Google Scholar
• Szulc P Biochemical bone turnover markers and osteoporosis in older men: where are we? J Osteoporos 2011 2011 704015 22220284
   PubMedGoogle Scholar
• Meier C Nguyen TV Center JR Seibel MJ Eisman JA Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology study J Bone Miner Res 2005 20 4 579 587 15765176
   PubMed Web of Science ®Google Scholar
• Theiler R Stahelin HB Kranzlin M Tyndall A Bischoff HA High bone turnover in the elderly Arch Phys Med Rehabil 1999 80 5 485 489 10326908
   PubMed Web of Science ®Google Scholar
• Adler RA Epidemiology and pathophysiology of osteoporosis in men Curr Osteoporos Rep 2006 4 3 110 115 16908000
   PubMedGoogle Scholar
• Herrara AL-EA Mateo J Gil J Ibarz E Garcia L Male osteoporosis: a review World J Orthop 2012 3 12 223 234 23362466
   PubMedGoogle Scholar
• Shimizu Y Sakai A Menuki K Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2-disrupted mice Bone 2011 48 5 1075 1086 21256255
   PubMed Web of Science ®Google Scholar
• Al-oanzi ZH Tuck SP Raj N Assessment of vitamin D status in male osteoporosis Clin Chem 2006 52 2 248 254 16339300
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA Conzelmann M Stahelin HB Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int 2006 17 5 656 663 16508700
   PubMed Web of Science ®Google Scholar
• Gielen E Boonen S Vanderschueren D Calcium and vitamin D supplementation in men J Osteoporos 2011 2011 875249 21876835
   PubMedGoogle Scholar
• Gupta R Sharma U Gupta N Effect of cholecalciferol and calcium supplementation on muscle strength and energy metabolism in vitamin D-deficient Asian Indians: a randomized, controlled trial Clin Endocrinol (Oxf) 2010 73 4 445 451 20455886
   PubMed Web of Science ®Google Scholar
• Behre HM Kliesch S Leifke E Link TM Nieschlag E Long-term effect of testosterone therapy on bone mineral density in hypogonadal men J Clin Endocrinol Metab 1997 82 8 2386 2390 9253305
   PubMed Web of Science ®Google Scholar
• Farhat G Yamout B Mikati MA Demirjian S Sawaya R El-Hajj Fuleihan G Effect of antiepileptic drugs on bone density in ambulatory patients Neurology 2002 58 9 1348 1353 12011279
   PubMed Web of Science ®Google Scholar
• Scane AC Francis RM Sutcliffe AM Francis MJ Rawlings DJ Chapple CL Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men Osteoporos Int 1999 9 1 91 97 10367034
   PubMed Web of Science ®Google Scholar
• Amin S Khosla S Sex- and age-related differences in bone microarchitecture in men relative to women assessed by high-resolution peripheral quantitative computed tomography J Osteoporos 2012 2012 129760 22496983
   PubMedGoogle Scholar
• Gennari L Bilezikian JP Osteoporosis in men: pathophysiology and treatment Curr Rheumatol Rep 2007 9 1 71 77 17437671
   PubMedGoogle Scholar
• Khosla S Riggs BL Atkinson EJ Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment J Bone Miner Res 2006 21 1 124 131 16355281
   PubMed Web of Science ®Google Scholar
• Sode M Burghardt AJ Kazakia GJ Link TM Majumdar S Regional variations of gender-specific and age-related differences in trabecular bone structure of the distal radius and tibia Bone 2010 46 6 1652 1660 20188877
   PubMed Web of Science ®Google Scholar
• Macdonald HM Nishiyama KK Kang J Hanley DA Boyd SK Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study J Bone Miner Res 2010 26 1 50 62 20593413
   PubMed Web of Science ®Google Scholar
• Burghardt AJ Kazakia GJ Ramachandran S Link TM Majumdar S Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia J Bone Miner Res 2009 25 5 983 993 19888900
   PubMed Web of Science ®Google Scholar
• Russo CR Lauretani F Seeman E Structural adaptations to bone loss in aging men and women Bone 2006 38 1 112 118 16242391
   PubMed Web of Science ®Google Scholar
• Seeman E During aging, men lose less bone than women because they gain more periosteal bone, not because they resorb less endosteal bone Calcif Tissue Int 2001 69 4 205 208 11730251
   PubMed Web of Science ®Google Scholar
• Seeman E The structural and biomechanical basis of the gain and loss of bone strength in women and men Endocrinol Metab Clin North Am 2003 32 1 25 38 12699291
   PubMed Web of Science ®Google Scholar
• Vanderschueren D Vandenput L Boonen S Lindberg MK Bouillon R Ohlsson C Androgens and bone Endocr Rev 2004 25 3 389 425 15180950
   PubMed Web of Science ®Google Scholar
• Callewaert F Venken K Ophoff J Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha FASEB J 2009 23 1 232 240 18809737
   PubMed Web of Science ®Google Scholar
• Sims NA Dupont S Krust A Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males Bone 2002 30 1 18 25 11792560
   PubMed Web of Science ®Google Scholar
• Olson LE Ohlsson C Mohan S The role of GH/IGF-I-mediated mechanisms in sex differences in cortical bone size in mice Calcif Tissue Int 2010 88 1 1 8 21113585
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation Just for men Available from: http://www.nof.org/articles/236 Accessed October 15, 2012
   Google Scholar
• Bass E French DD Bradham DD Rubenstein LZ Risk-adjusted mortality rates of elderly veterans with hip fractures Ann Epidemiol 2007 17 7 514 519 17420142
   PubMed Web of Science ®Google Scholar
• Cooper C Campion G Melton LJ3rd Hip fractures in the elderly: a world-wide projection Osteoporos Int 1992 2 6 285 289 1421796
   PubMed Web of Science ®Google Scholar
• Johnell O Kanis JA An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 2006 17 12 1726 1733 16983459
   PubMed Web of Science ®Google Scholar
• Poor G Atkinson EJ Lewallen DG O’Fallon WM Melton LJ3rd Age-related hip fractures in men: clinical spectrum and short-term outcomes Osteoporos Int 1995 5 6 419 426 8695962
   PubMed Web of Science ®Google Scholar
• Duque G Troen BR Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome J Am Geriatr Soc 2008 56 5 935 941 18454751
   PubMed Web of Science ®Google Scholar
• Snyder PJ Peachey H Hannoush P Effect of testosterone treatment on bone mineral density in men over 65 years of age J Clin Endocrinol Metab 1999 84 6 1966 1972 10372695
   PubMed Web of Science ®Google Scholar
• Licata A Osteoporosis in men: suspect secondary disease first Cleve Clin J Med 2003 70 3 247 254 12678216
   PubMed Web of Science ®Google Scholar
• Kanis JA Bianchi G Bilezikian JP Towards a diagnostic and therapeutic consensus in male osteoporosis Osteoporos Int 2011 22 11 2789 2798 21509585
   PubMed Web of Science ®Google Scholar
• Gruenewald DA Matsumoto AM Testosterone supplementation therapy for older men: potential benefits and risks J Am Geriatr Soc 2003 51 1 101 115 12534854
   PubMed Web of Science ®Google Scholar
• Cusano NE Costa AG Silva BC Bilezikian JP Therapy of osteoporosis in men with teriparatide J Osteoporos 2011 2011 463675 22132345
   PubMedGoogle Scholar
• Girotra M Rubin MR Bilezikian JP Anabolic skeletal therapy for osteoporosis Arq Bras Endocrinol Metabol 2006 50 4 745 754 17117299
   PubMedGoogle Scholar
• Kaufman JM Orwoll E Goemaere S Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy Osteoporos Int 2005 16 5 510 516 15322742
   PubMed Web of Science ®Google Scholar
• Finkelstein JS Leder BZ Burnett SM Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men J Clin Endocrinol Metab 2006 91 8 2882 2887 16684825
   PubMed Web of Science ®Google Scholar
• Kurland ES Heller SL Diamond B McMahon DJ Cosman F Bilezikian JP The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)] Osteoporos Int 2004 15 12 992 997 15175844
   PubMed Web of Science ®Google Scholar
• Kraenzlin ME Meier C Parathyroid hormone analogues in the treatment of osteoporosis Nat Rev Endocrinol 2011 7 11 647 656 21750510
   PubMed Web of Science ®Google Scholar
• Finkelstein JS Hayes A Hunzelman JL Wyland JJ Lee H Neer RM The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 2003 349 13 1216 1226 14500805
   PubMed Web of Science ®Google Scholar
• Toth E Csupor E Meszaros S The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures – an open label study Bone 2005 36 1 47 51 15664001
   PubMed Web of Science ®Google Scholar
• Trovas GP Lyritis GP Galanos A Raptou P Constantelou E A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers J Bone Miner Res 2002 17 3 521 527 11874243
   PubMed Web of Science ®Google Scholar
• Honig S Osteoporosis – new treatments and updates Bull NYU Hosp Jt Dis 2010 68 3 166 170 20969546
   PubMedGoogle Scholar
• Smith MR Fallon MA Lee H Finkelstein JS Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 2004 89 8 3841 3846 15292315
   PubMed Web of Science ®Google Scholar
• Gonnelli S Cepollaro C Montagnani A Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study Calcif Tissue Int 2003 73 2 133 139 14565594
   PubMed Web of Science ®Google Scholar
• Orwoll ES Oviatt SK McClung MR Deftos LJ Sexton G The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation Ann Intern Med 1990 112 1 29 34 2152844
   PubMed Web of Science ®Google Scholar
• Anderson FH Francis RM Bishop JC Rawlings DJ Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures Age Ageing 1997 26 5 359 365 9351480
   PubMed Web of Science ®Google Scholar
• Lamy O Sandini L Pache I Fatio S Burnand J Burckhardt P Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years J Endocrinol Invest 2003 26 8 728 732 14669826
   PubMed Web of Science ®Google Scholar
• Boonen S Reginster JY Kaufman JM Fracture risk and zoledronic acid therapy in men with osteoporosis N Engl J Med 2012 367 18 1714 1723 23113482
   PubMed Web of Science ®Google Scholar
• Piper PKJr Gruntmanis U Management of osteoporosis in the aging male: focus on zoledronic acid Clin Interv Aging 2009 4 289 303 19750231
   PubMed Web of Science ®Google Scholar
• Sewerynek E Stuss M The role of I.V. ibandronate administration in osteoporosis therapy Endokrynol Pol 2011 62 1 51 60 21365580
   PubMed Web of Science ®Google Scholar
• Black DM Delmas PD Eastell R Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 2007 356 18 1809 1822 17476007
   PubMed Web of Science ®Google Scholar
• Black DM Reid IR Boonen S The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 2012 27 2 243 254 22161728
   PubMed Web of Science ®Google Scholar
• Piters E de Freitas F Nielsen TL Andersen M Brixen K Van Hul W Association study of polymorphisms in the SOST gene region and parameters of bone strength and body composition in both young and elderly men: data from the Odense Androgen Study Calcif Tissue Int 2011 90 1 30 39 22076526
   PubMed Web of Science ®Google Scholar
• Kaufman JM Reginster JY Boonen S Treatment of osteoporosis in men Bone 2012 53 1 134 144 23201268
   PubMed Web of Science ®Google Scholar
• Gagnon C Ebeling PR Recent advances in managing osteoporosis F1000 Med Rep 2009 1 pii 96
   Google Scholar
• Morgans AK Smith MR RANKL-targeted therapies: the next frontier in the treatment of male osteoporosis J Osteoporos 2011 2011 941310 22013547
   PubMedGoogle Scholar
• Baron R Hesse E Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives J Clin Endocrinol Metab 2012 97 2 311 325 22238383
   PubMed Web of Science ®Google Scholar
• Li X Ominsky MS Warmington KS Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 2009 24 4 578 588 19049336
   PubMed Web of Science ®Google Scholar
• Lewiecki EM Sclerostin: a novel target for intervention in the treatment of osteoporosis Discov Med 2011 12 65 263 273 22031665
   PubMed Web of Science ®Google Scholar
• Cho HY Choi HJ Sun HJ Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis Bone 2010 47 2 263 271 20472109
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B Harris SS Krall EA Dallal GE Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 1997 337 10 670 676 9278463
   PubMed Web of Science ®Google Scholar
• Trivedi DP Doll R Khaw KT Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial BMJ 2003 326 7387 469 12609940
   PubMed Web of Science ®Google Scholar
• Compston J Clinical and therapeutic aspects of osteoporosis Eur J Radiol 2009 71 3 388 391 19660883
   PubMed Web of Science ®Google Scholar
• Moyad MA Complementary/alternative therapies for reducing hot fashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women Urology 2002 59 4 Suppl 1 20 33 11937433
   PubMed Web of Science ®Google Scholar
• Avenell A Gillespie WJ Gillespie LD O’Connell D Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis Cochrane Database Syst Rev 2009 2 CD000227 19370554
   PubMed Web of Science ®Google Scholar
• Boonen S Lips P Bouillon R Bischoff-Ferrari HA Vanderschueren D Haentjens P Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials J Clin Endocrinol Metab 2007 92 4 1415 1423 17264183
   PubMed Web of Science ®Google Scholar
• Tang BM Eslick GD Nowson C Smith C Bensoussan A Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis Lancet 2007 370 9588 657 666 17720017
   PubMed Web of Science ®Google Scholar
• Ringe JD Dorst A Kipshoven C Rovati LC Setnikar I Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate Osteoporos Int 1998 8 1 47 52 9692077
   PubMed Web of Science ®Google Scholar
• Watkins BA Li Y Lippman HE Seifert MF Omega-3 polyunsaturated fatty acids and skeletal health Exp Biol Med (Maywood) 2001 226 6 485 497 11395919
   PubMed Web of Science ®Google Scholar
• Fernandes G Bhattacharya A Rahman M Zaman K Banu J Effects of n-3 fatty acids on autoimmunity and osteoporosis Front Biosci 2008 13 4015 4020 18508495
   PubMed Web of Science ®Google Scholar
• Weiler HA Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs Pediatr Res 2000 47 5 692 697 10813598
   PubMed Web of Science ®Google Scholar
• Weiler HA Fitzpatrick-Wong SC Modulation of essential (n-6):(n-3) fatty acid ratios alters fatty acid status but not bone mass in piglets J Nutr 2002 132 9 2667 2672 12221227
   PubMed Web of Science ®Google Scholar
• Shen CL Yeh JK Rasty J Improvement of bone quality in gonad-intact middle-aged male rats by long-chain n-3 polyunsaturated fatty acid Calcif Tissue Int 2007 80 4 286 293 17406770
   PubMed Web of Science ®Google Scholar
• Hogstrom M Nordstrom P Nordstrom A n-3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study Am J Clin Nutr 2007 85 3 803 807 17344503
   PubMed Web of Science ®Google Scholar
• Banu J Bhattacharya A Rahman M O’Shea M Fernandes G Effects of conjugated linoleic acid and exercise on bone mass in young male Balb/C mice Lipids Health Dis 2006 5 7 16556311
   PubMed Web of Science ®Google Scholar
• Soung DY Devareddy L Khalil DA Soy affects trabecular microarchitecture and favorably alters select bone-specific gene expressions in a male rat model of osteoporosis Calcif Tissue Int 2006 78 6 385 391 16830200
   PubMed Web of Science ®Google Scholar
• Banu J Varela E Fernandes G Alternative therapies for the prevention and treatment of osteoporosis Nutr Rev 2012 70 1 22 40 22221214
   PubMed Web of Science ®Google Scholar
• Chai SC Hooshmand S Saadat RL Payton ME Brummel-Smith K Arjmandi BH Daily apple versus dried plum: impact on cardiovascular disease risk factors in postmenopausal women J Acad Nutr Diet 2012 112 8 1158 1168 22818725
   PubMed Web of Science ®Google Scholar
• Hooshmand S Chai SC Saadat RL Payton ME Brummel-Smith K Arjmandi BH Comparative effects of dried plum and dried apple on bone in postmenopausal women Br J Nutr 2011 106 6 923 930 21736808
   PubMed Web of Science ®Google Scholar
• Kondo KL Osteoporotic vertebral compression fractures and vertebral augmentation Semin Intervent Radiol 2008 25 4 413 424 21326583
   PubMedGoogle Scholar
• Levine JP Pharmacologic and nonpharmacologic management of osteoporosis Clin Cornerstone 2006 8 1 40 53 17591575
   PubMedGoogle Scholar
• Schwarz P Jorgensen NR Mosekilde L Vestergaard P The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men J Osteoporos 2011 2011 259818 21776371
   PubMedGoogle Scholar